Multivariate random-intercept logistic regressions of experiencing viral load suppression, virological failure and HIV drug resistance for adults and children.

<p>Note: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.</p>*<p>Moderate and poor adherence categories were combined in the analysis of HIV drug resistance among children.</p>†<p>Non-significant factor in the final model.</p

Patient characteristics at ART start by age.

<p>Note: BMI, body mass index, categorized for children according to Cole <i>et al</i>. classification <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049091#pone.0049091-Cole1" target="_blank">[32]</a>.</p

Flow chart of the patients included in the study.

<p>Flow chart of the patients included in the study.</p

Variation in the time between two consecutive visits with length of follow-up since ART initiation in adults (a) and children (b).

<p>Variation in the time between two consecutive visits with length of follow-up since ART initiation in adults (a) and children (b).</p

Patient distribution of adherence to clinic visits by outcome in adults (a) and children (b).

<p>Patient distribution of adherence to clinic visits by outcome in adults (a) and children (b).</p

RAMS among patients with virological failure (VL>5.000 copies/ml) amplified and evaluated by genotyping.

<p>RAMS among patients with virological failure (VL>5.000 copies/ml) amplified and evaluated by genotyping.</p

Patient's disposition.

<p>Patient's disposition.</p

Virological failure rates over time in different resource limited settings.

2<p> <b>Ferradini et al. Lancet 2006; 367:1335–42. ³ Ferradini et al. AIDS 2007, 21:2293–2301.</b></p

NNRTI's resistance mutations prevalence.

<p>NNRTI's resistance mutations prevalence.</p

Patients with VL >5.000 copies/ml (N = 55).

<p>Patients with VL >5.000 copies/ml (N = 55).</p